New insights into hepatitis B and hepatitis delta virus entry

Future Virology

Volumn 3, Issue 3, 2008, Pages 253-264

  Urban, Stephan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

HBV; HBV entry inhibitor; HDV; HepaRG cells; Infection inhibition; Myrcludex B; Myristic acid; Myristoylated preS peptide

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; DIHYDROLIPOAMIDE DEHYDROGENASE; ENFUVIRTIDE; ENTECAVIR; FLUORESCENT DYE; GLYCOSAMINOGLYCAN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; LIPOPEPTIDE; M PROTEIN; MEMBRANE PROTEIN; MYRCLUDEX B; PEGINTERFERON ALPHA; PHOSPHOLIPID; PROTEOHEPARAN SULFATE; TELBIVUDINE; VIRUS ENVELOPE PROTEIN; VITRONECTIN;

ACYLATION; AMINO TERMINAL SEQUENCE; CELL LINE; CELL MEMBRANE; CELL SURFACE; CYTOSOL; DELTA AGENT HEPATITIS; ENDOCYTOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HEPATOMA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; LIVER CELL; LIVER CELL CARCINOMA; MEMBRANE FUSION; MYRISTYLATION; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SCANDENTIA; VIRION; VIRUS ATTACHMENT; VIRUS ENVELOPE; VIRUS TRANSMISSION;

HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; TUPAIA BELANGERI;

EID: 44149124526     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.3.253     Document Type: Review

References (73)

1. Seeger C, Mason WS: Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64(1), 51-68 (2000).
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP: Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28, 112-125 (2006).
3. Kao JH, Chen DS: Global control of hepatitis B virus infection. Lance Infect. Dis. 2(7), 395-403 (2002).
4. Lok AS: Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S303-S309 (2004).
5. Asselah T, Ripault MP, Castelnau C, Giuily N, Boyer N. Marcellin P: The current status of antiviral therapy of chronic hepatitis B. J. Clin. Virol. 34(Suppl. 1), S115-S124 (2005).
6. Locarnini S, Hatzakis A, Heathcote J et al.: Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 9(5), 679-693 (2004).
7. Glebe D, Urban S: Viral and cellular determinants involved in hepadnaviral entry. World J. Gastroenterol. 13(1), 22-38 (2007).
8. Acs G, Sells MA, Purcell RH et al.: Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc. Natl Acad. Sci. USA 84(13), 4641-4644 (1987).
9. Gripon P, Diot C, Theze N et al.: Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J. Virol. 62(11), 4136-4143 (1988).
10. Walter E, Keist R, Niederost B, Pult I, Blum HE: Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 24(1), 1-5 (1996).
11. Guidotti LG, Matzke B, Schaller H, Chisari FV: High-level hepatitis B virus replication in transgenic mice. J. Virol. 69(10), 6158-6169 (1995).
12. Ladner SK, Otto MJ, Barker CS et al.: Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41(8), 1715-1720 (1997).
13. Sells MA, Chen ML, Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl Acad. Sci. USA 84(4), 1005-1009 (1987).
14. Weiss L, Kekule AS. Jakubowski U, Burgelt E, Hofschneider PH: The HBV-producing cell line HepG2-4A5: a new in vitro system for studying the regulation of HBV replication and for screening anti-hepatitis B virus drugs. Virology 216(1), 214-218 (1996).
15. Mason WS, Seal G. Summers J: Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J. Virol.. 36(3), 829-836 (1980).
16. Summers J, Smolec JM, Snyder R: A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc. Natl Acad. Sci. USA 75(9), 4533-4537 (1978).
17. Ochiya T, Tsurimoto T, Ueda K, Okubo K, Shiozawa M, Matsubara K: An in vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes. Proc. Natl Acad. Sci. USA 86(6), 1875-1879 (1989).
18. Rijntjes PJ, Moshage HJ, Yap SH: In vitro infection of primary cultures of cryopreserved adult human hepatocytes with hepatitis B virus. Virus Res. 10(1), 95-109 (1988).
19. Gripon P, Diot C, Guguen-Guillouzo C: Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology 192(2), 534-540 (1993).
20. Bruss V, Hagelstein J, Gerhardt E, Galle PR: Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology 218(2), 396-399 (1996).
21. Gripon P, Le SJ, Rumin S, Guguen-Guillouzo C: Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213(2), 292-299 (1995).
22. Blanchet M, Sureau C: Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues. J. Virol. 81(11), 5841-5849 (2007).
23. Engelke M, Mills K, Seitz S et al.: Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 43(4), 750-760 (2006).
24. Le Seyec J. Chouteau P, Cannie I, Guguen-Guillouzo C. Gripon P: Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J Virol. 73(3), 2052-2057 (1999).
25. Jaoude GA. Molina S. Maurel P, Sureau C: Myristoylation signal transfer from the large to the middle or the small HBV envelope protein leads to a loss of HDV particles infectivity. Virology 365(1), 204-209 (2007).
26. Schulze A. Gripon P, Urban S: Hepatitis B virus infection initates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepalology 46(6), 1759-1768 (2007).
27. Li Q, Ding M, Wang H: [The infection of hepatitis D virus in adult tupaia]. Zhonghua Yi Xue Za Zhi 75(10). 611-640 (1995).
28. Kock J, Nassal M. MacNelly S, Baumert TF, Blum HE: Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J. Virol. 75(11), 5084-5089 (2001).
29. Dandri M. Burda MR, Zuckerman DM et al.: Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J. Hepatol. 42(1), 54-60 (2005).
30. Petersen J, Dandri M, Mier W et al.: Prevention of hepatitis B virus Infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26(3), 335-341 (2008).
31. Glebe D, Urban S, Knoop EV et al.: Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupala hepatocytes. Gastroenteraogy 129(1), 234-245 (2005).
32. Barrera A, Guerra B, Lee H, Lanford RE: Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes. J. Virol. 78(10), 5233-5243 (2004).
33. Gripon P, Rumin S, Urban S et al.: Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl Acad. Sci. USA 99 (24), 15655-15660 (2002).
34. Jaoude GA, Sureau C: Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus. J. Virol. 79(16), 10460-10466 (2005).
35. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C: The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168(1), 66-73 (2007).
36. Cerec V, Glaise D, Garnier D et al.: Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45(4), 957-967 (2007).
37. Aninat C, Piton A. Glaise D et al.: Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HcpaRG cells. Drug Metab. Dispos. 34(1), 75-83 (2006).
38. Le VM, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O: Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur. J. Pharm. Sci. 28(1-2), 109-117 (2006).
39. Parent R, Marion MJ. Furio L, Trepo C, Petit MA: Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 126 (4), 1147-1156 (2004).
40. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH: Large surface proteins of hepatitis B virus containing the pre-S sequence. J. Virol. 52(2), 396-402 (1984).
41. Bruss V: Hepatitis B virus morphogenesis. Wold J. Gastroenterol. 13(1), 65-73 (2007).
42. Bruss V, Ganem D: The role of envelope proteins in hepatitis B virus assembly. Proc. Natl Acad. Sci. USA 88(3), 1059-1063 (1991).
43. Park JH: [Hepatitis B virus surface antigen: a multifaceted protein]. Korean J. Hepatol. 10(4), 248-259 (2004).
44. Prange R, Streeck RE: Novel transmembrane topology of the hepatitis B virus envelope proteins. EMBO J 14(2), 247-256 (1995).
45. Bruss V, Lu X, Thomssen R, Gerlich WH: Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J. 13(10), 2273-2279 (1994).
46. Loffler-Mary H, Werr M, Prange R: Sequence-specific repression of cotranslational translocation of the hepatitis B virus envelope proteins coincides with binding of heat shock protein Hsc70. Virology 235(1), 144-152 (1997).
47. Chai N, Gudima S, Chang J, Taylor J: Immunoadhesins containing pre-S domains of hepatitis B virus large envelope protein are secreted and inhibit virus infection. J. Virol. 81(10), 4912-4918 (2007).
48. Dryden KA, Wieland SF, Whitten-Bauer C, Gerin JL, Chisari FV, Yeager M: Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol. Cell 22(6), 843-850 (2006).
49. Seitz S. Urban S, Antoni C, Bottcher B: Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J. 26(18), 4160-4167 (2007).
50. Barrera A, Guerra B, Notvall L, Lanford RE: Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J. Virol. 79(15), 9786-9798 (2005).
51. Gripon P. Cannie I, Urban S: Efficient Inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79(3), 1613-1622 (2005).
52. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH: Pre-S1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J. Virol. 77(17), 9511-9521 (2003).
53. Neurath AR, Kent SB, Parker K et al.: Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine 4(1). 35-37 (1986).
54. Ryu CJ, Gripon P, Park HR et al.: In vitro neutralization of hepatitis B virus by, monoclonal antibodies against the viral surface antigen. J. Med. Virol. 52(2). 226-233 (1997).
55. Zhang P, Yu MY, Venable R, Alter HJ, Shih JW: Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. Proc Natl Acad. Sci. USA 103(24), 9214-9219 (2006).
56. Neurath AR, Kent SB, Strick N, Parker K: Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46(3), 429-436 (1986).
57. Neurath AR, Strick N, Sproul P, Ralph HE, Valinsky J: Detection of receptors for hepatitis B virus on cells of extrahepatic origin. Virology 176(2), 448-457 (1990).
58. Fernholz D, Stemler M, Brunetto M, Bonino F, Will H: Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein. J. Hepatol. 13(Suppl. 4), S102-S104 (1991).
59. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H: Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 194(1), 137-148 (1993).
60. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P: Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity, J. Virol. 72(7), 5573-5578 (1998).
61. Stoeckl L, Funk A, Kopitzki A et al.: Identification of a structural motif crucial for infectivity of hepatitis B viruses. Proc. Natl Acad. Sci. USA 103(17), 6730-6734 (2006).
62. Oess S, Hildt E: Novell cell permeable motif derived from the PreS2-domain of hepatitis B virus surface antigens. Gene Ther. 7(9), 750-758 (2000).
63. Gudima S, Meier A, Dunbrack R, Taylor J. Bruss V: Two potentially important elements of the hepatitis B virus large envelope protein are dispensable for the Infectivity of hepatitis delta virus. J. Virol. 81(8), 4343-4347 (2007).
64. Lepere C, Regeard M, Le SJ, Gripon P: The translocation motif of hepatitis B virus envelope proteins is dispensable for infectivity. J. Virol. 81(14), 7816-7818 (2007).
65. Hildt E, Hofschneider PH: The preS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Recent Results Cancer Res. 154, 315-329 (1998).
66. Hildt E. Munz B, Saber G, Reifenberg K, Hofschneider PH: The preS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 21(4), 525-535 (2002).
67. Glebe D: Attachment sites and neutralising epitopes of hepatitis B virus. Minerva Gastroenterol. Dietol. 52(1), 3-21 (2006).
68. Chcjnacki J, Anderson DA, Grgacic EV: A hydrophobic domain in the large envelope protein is essential for fusion of duck hepatitis B virus at the late endosome. J. Virol. 79(23), 14945-14955 (2005).
69. Jaoude GA, Sureau C: Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J. Virol. 81(23), 13057-13066 (2007).
70. Satoh O, Umeda M, Imai H, Tunoo H, Inoue K: Lipid composition of hepatitis B virus surface antigen particles and the particle-producing human hepatoma cell lines. J. Lipid Res. 31(7), 1293-1300 (1990).
71. Leistner CM, Gruen-Bernhard S, Glebe D: Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol. 10(1), 122-133 (2008).
72. Eckert DM, Kim PS: Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70. 777-810 (2001).
73. Greenberg M, Cammack N, Salgo M, Smiley L: HIV fusion and its inhibition in antiretroviral therapy. Rev. Med. Virol. 14(5), 321-337 (2004).